Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN, United States.
Department of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, TN, United States.
Front Immunol. 2022 May 12;13:894534. doi: 10.3389/fimmu.2022.894534. eCollection 2022.
Secondary bacterial infections can exacerbate SARS-CoV-2 infection, but their prevalence and impact remain poorly understood. Here, we established that a mild to moderate infection with the SARS-CoV-2 USA-WA1/2020 strain increased the risk of pneumococcal (type 2 strain D39) coinfection in a time-dependent, but sex-independent, manner in the transgenic K18-hACE2 mouse model of COVID-19. Bacterial coinfection increased lethality when the bacteria was initiated at 5 or 7 d post-virus infection (pvi) but not at 3 d pvi. Bacterial outgrowth was accompanied by neutrophilia in the groups coinfected at 7 d pvi and reductions in B cells, T cells, IL-6, IL-15, IL-18, and LIF were present in groups coinfected at 5 d pvi. However, viral burden, lung pathology, cytokines, chemokines, and immune cell activation were largely unchanged after bacterial coinfection. Examining surviving animals more than a week after infection resolution suggested that immune cell activation remained high and was exacerbated in the lungs of coinfected animals compared with SARS-CoV-2 infection alone. These data suggest that SARS-CoV-2 increases susceptibility and pathogenicity to bacterial coinfection, and further studies are needed to understand and combat disease associated with bacterial pneumonia in COVID-19 patients.
继发细菌性感染可使 SARS-CoV-2 感染恶化,但它们的流行程度和影响仍知之甚少。在这里,我们证实,在 COVID-19 的 K18-hACE2 转基因小鼠模型中,轻度至中度感染 SARS-CoV-2 USA-WA1/2020 株会以时间依赖但性别无关的方式增加肺炎球菌(D39 型)合并感染的风险。当在病毒感染后 5 或 7 天(pvi)而不是在 3 天 pvi 开始细菌合并感染时,细菌合并感染会增加死亡率。在 7 天 pvi 合并感染的组中,细菌生长伴随着中性粒细胞增多,而在 5 天 pvi 合并感染的组中,B 细胞、T 细胞、IL-6、IL-15、IL-18 和 LIF 减少。然而,在细菌合并感染后,病毒载量、肺病理学、细胞因子、趋化因子和免疫细胞激活基本上没有变化。对感染解决后一周以上存活的动物进行检查表明,与单独感染 SARS-CoV-2 相比,免疫细胞激活仍然很高,并在合并感染的动物肺部加剧。这些数据表明,SARS-CoV-2 增加了对细菌合并感染的易感性和致病性,需要进一步研究来理解和对抗 COVID-19 患者中与细菌性肺炎相关的疾病。